These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 16525905)

  • 1. [Pharmacological treatment resistant schizophrenia].
    Cervera Enguix S; Seva Fernández A
    Actas Esp Psiquiatr; 2006; 34(1):48-54. PubMed ID: 16525905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Practical aspects of drug resistance in schizophrenia].
    Jarema M; Kucińska M
    Psychiatr Pol; 2000; 34(5):721-40. PubMed ID: 11202015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
    Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F
    Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Limitations of efficacy of chemotherapies in schizophrenia].
    Kapsambelis V; Ginestet D
    Encephale; 1991; 17(6):531-5. PubMed ID: 1687214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine for elderly non-responsive schizophrenia patients.
    Mazeh D; Paleacu D; Barak Y
    Psychiatry Res; 2008 Jan; 157(1-3):265-7. PubMed ID: 17928067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach.
    Santone G; Rucci P; Muratori ML; Monaci A; Ciarafoni C; Borsetti G
    Psychiatry Res; 2008 Apr; 158(3):324-34. PubMed ID: 18262656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
    Maneesakorn S; Robson D; Gournay K; Gray R
    J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Functionality as a goal in the treatment of schizophrenia].
    García B;
    Actas Esp Psiquiatr; 2002; 30(5):312-25. PubMed ID: 12372228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.